Leptin appears to exert a dual action in experimental NAFLD models; it protects against liver steatosis, at least in the early stages of the disease, but it also acts as an inflammatory and fibrogenic mediator when the disease persists or continues (133). Here, LEP is linked to Hepatic steatosis.